drugset / Trial / NCT01183949
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Phase 1/2
Completed
18 enrolled
Astex Pharmaceuticals, Inc.
Multiple Myeloma Research Consortium · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
Timeline
- Start
- 2010-11
- Primary completion
- 2014-12
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AT7519 | Small molecule | 14 mg/m2 | Intravenous |
| Subject | AT7519 | Small molecule | 21 mg/m2 | Intravenous |
| Subject | AT7519 | Small molecule | 27 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |